MedPath

A study of exercise versus rest in myasthenia gravis

Phase 3
Completed
Conditions
Health Condition 1: G700- Myasthenia gravis
Registration Number
CTRI/2019/11/021869
Lead Sponsor
Prinicipal Investigator
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
40
Inclusion Criteria

1. MG patients attending the neurology Outdoor or indoor services of SGPGIMS.

2. MGFA score of stage II to III.

3. Able to undergo 6minute walk test

Exclusion Criteria

1. Enrolled in another trial. 2. Contraindications to exercise like coronary artery disease and stroke and pulmonary disease, osteoarthritis, pregnancy or medical condition reducing survival to less than 2 years.

3. Hospitalization in past 8 weeks. 4. MGFA score of stage I, IV or V. 5. MGQOL score > 45.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
MGQOL-15 scoreTimepoint: 1,2 and 3 months <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
1. Increase in the dose of AchEIs drugs or additional immunosuppression or use of PE,IVIG. <br/ ><br>2. Myasthenic muscle score: at 1,2 and 3 month. <br/ ><br>3. Change in MGADL. <br/ ><br>4. Grip strength. <br/ ><br>5. Six min walk test. <br/ ><br>6. RNS in Trapezius <br/ ><br>7. Micro RNA: -150 -5P and micro RNA- 21- 5P. <br/ ><br>8. Endorphin and its receptors.Timepoint: 1,2 and 3 months
© Copyright 2025. All Rights Reserved by MedPath